NVO SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Novo Nordisk A/S Investors Have Opportunity to Lead Class Action Lawsuit!
NEW YORK, NY / ACCESS Newswire / February 11, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, ...
NVO CLASS ACTION UPDATE: Novo Nordisk Investors are Reminded to Contact BFA Law before Imminent March 25 Deadline
Novo Nordisk is a healthcare company focused on the research, development, manufacturing, and distribution of pharmaceutical products globally. During the relevant period, Novo Nordisk was conducting ...
Invesco EQV International Equity Fund Q4 2024 Commentary
Class A shares underperformed the MSCI ACWI ex USA Index. During the quarter, we initiated four new positions and exited one ...
MedPage Today1h
FDA Pauses Obesity Drug Study; Diabetic Eye Therapy OK'd; 'Misleading' Super Bowl Ad
Novo Nordisk announced plans for a longer phase III trial testing its investigational obesity drug CagriSema, with regulatory ...
Genmab stock rating raised, price target cut by BNP Paribas Exane
Exane analyst Victor Floch upgraded Genmab (NASDAQ:GMAB) A/S shares from Underperform to Neutral, adjusting the price target ...
Invesco EQV European Equity Fund Q4 2024 Commentary
Class A shares underperformed the MSCI Europe Index for the quarter. The leading detractors from relative return were stock ...